Vivos Valuation Multiples

Discover Vivos' revenue and EBITDA valuation multiples and M&A history, alongside public comparables like Myomo, Ortoma, Elutia, Optomed and more.

Vivos Overview

About Vivos

Vivos Inc is a radiation oncology medical device company. It is engaged in the development of RadioGel which is a brachytherapy device comprising insoluble particles delivered by needle injection using a water-polymer composite for high-dose treatment of non-resectable solid tumors. IsoPet is another product of the company used for the treatment of solid tumors in animals. The company derives revenue through sales of its products.


Founded

1994

HQ

United States

Employees

1

Financials (FY)

Revenue: $68K
EBITDA: ($3M)

EV

$42M

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Vivos Financials

Vivos reported last fiscal year revenue of $68K and negative EBITDA of ($3M).

In the same fiscal year, Vivos generated ($60K) in gross profit, ($3M) in EBITDA losses, and had net loss of ($3M).


Vivos P&L

In the most recent fiscal year, Vivos reported revenue of $68K and EBITDA of ($3M).

Vivos is unprofitable as of last fiscal year, with gross margin of (87%), EBITDA margin of (4628%), and net margin of (4484%).

See analyst estimates for Vivos
Last FY202320242025202620272028
Revenue$68K$20K$28K$68K
Gross Profit($60K)($6K)($3K)($60K)
Gross Margin(87%)(31%)(11%)(87%)
EBITDA($3M)($3M)($3M)($3M)
EBITDA Margin(4628%)(14324%)(9303%)(4628%)
EBIT Margin(4629%)(14324%)(9303%)(4629%)
Net Profit($3M)($3M)($3M)($3M)
Net Margin(4484%)(14845%)(10396%)(4484%)

Financial data powered by Morningstar, Inc.

Vivos Stock Performance

Vivos has current market cap of $44M, and enterprise value of $42M.

Market Cap Evolution


Vivos' stock price is $0.09.

Vivos share price increased by 47.0% in the last 30 days, and decreased by 23.4% in the last year.

Vivos has an EPS (earnings per share) of $-0.01.

See more trading valuation data for Vivos
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$42M$44M4.9%47.0%30.2%-23.4%$-0.01

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Vivos Valuation Multiples

Vivos trades at 614.8x EV/Revenue multiple, and (13.3x) EV/EBITDA.

See NTM and 2027E valuation multiples for Vivos

Vivos Financial Valuation Multiples

As of July 8, 2026, Vivos has market cap of $44M and EV of $42M.

Vivos has a P/E ratio of (14.5x).

Last FY202320242025202620272028
EV/Revenuen/mn/mn/mn/m
EV/EBITDA(13.3x)(15.0x)(16.1x)(13.3x)
EV/EBIT(13.3x)(15.0x)(16.1x)(13.3x)
EV/Gross Profitn/mn/mn/mn/m
P/E(14.5x)(15.4x)(15.3x)(14.5x)
EV/FCF(19.5x)(32.5x)(25.0x)(19.5x)

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Vivos Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Vivos Margins & Growth Rates

In the most recent fiscal year, Vivos reported gross margin of (87%), EBITDA margin of (4628%), and net margin of (4484%).

See estimated margins and future growth rates for Vivos

Vivos Margins

Last FY20242025202720282029
Gross Margin(87%)(11%)(87%)
EBITDA Margin(4628%)(9303%)(4628%)
EBIT Margin(4629%)(9303%)(4629%)
Net Margin(4484%)(10396%)(4484%)
FCF Margin(3160%)(6015%)(3160%)

Vivos Growth Rates

23/2424/2526/2727/2828/29
Revenue Growth44%144%
Gross Profit Growth(51%)1903%
EBITDA Growth(7%)22%
EBIT Growth(7%)22%
Net Profit Growth1%5%
FCF Growth30%28%

Data powered by FactSet, Inc. and Morningstar, Inc.

Vivos Operational KPIs

Vivos' revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $3.1M for the same period.

Access forward-looking KPIs for Vivos
Last FY202320242025202620272028
Revenue per Employee$0.1M---
Opex per Employee$3.1M---
G&A Expenses to Revenue4026%10535%8133%4026%
R&D Expenses to Revenue515%3757%1160%515%
Opex to Revenue4541%14293%9292%4541%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Vivos Competitors

Vivos competitors include Myomo, Ortoma, Elutia, Optomed, OssDsign, RenovoRx, Episurf Medical, Singular Health, Baumer and Biohit.

Most Vivos public comparables operate across Medical Devices, DeepTech and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
Myomo1.2x1.1x(4.2x)(4.6x)
Ortoma5.9x6.1x(94.2x)(24.7x)
Elutia1.5x1.5x(1.4x)(1.3x)
Optomed1.8x1.8x(8.8x)(13.8x)
OssDsign1.4x1.6x(7.0x)(6.3x)
RenovoRx26.6x13.6x(2.4x)-
Episurf Medical32.8x-(9.0x)-
Singular Health280.9x-(9.3x)-

This data is available for Pro users. Sign up to see all Vivos competitors and their valuation data.

Start Free Trial

Acquisitions by Vivos

Vivos has acquired 1 company to date.

Last acquisition by Vivos was on July 15th 2025. Vivos acquired Nice-Pak Products for undisclosed valuation.

See M&A valuation multiples

Latest Acquisitions by Vivos

Nice-Pak Products
Description
Nice-Pak Products is a New Hyde Park-headquartered manufacturer of wet wipes, including sanitizing, baby, flushable, and surface disinfectant varieties produced in facilities across the United States, United Kingdom, and Mexico. Founded in 1960, it supplies private-label products to retailers like Walmart and Procter & Gamble, with production capacity exceeding billions of wipes annually using biodegradable materials.
HQ CountryUnited States
HQ City
New York City, NY
Deal Date15 Jul 2025
Valuationundisclosed
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Vivos acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Vivos

When was Vivos founded?Vivos was founded in 1994.
Where is Vivos headquartered?Vivos is headquartered in United States.
How many employees does Vivos have?As of today, Vivos has over 1 employees.
Is Vivos publicly listed?Yes, Vivos is a public company listed on OTCM.
What is the stock symbol of Vivos?Vivos trades under RDGL ticker.
Who are competitors of Vivos?Vivos main competitors include Myomo, Ortoma, Elutia, Optomed, OssDsign, RenovoRx, Episurf Medical, Singular Health, Baumer, Biohit.
What is the current market cap of Vivos?Vivos' current market cap is $44M.
What is the current revenue of Vivos?Vivos' last fiscal year revenue is $68K.
What is the current EV/Revenue multiple of Vivos?Current revenue multiple of Vivos is 614.8x.
Is Vivos profitable?No, Vivos is not profitable.
How many companies Vivos has acquired to date?As of July 2026, Vivos has acquired 1 company.
What was the largest acquisition by Vivos?None of the M&A deals Vivos has completed have disclosed valuations.
In how many companies Vivos has invested to date?Vivos hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Vivos

Lists including Vivos

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial